Back to top

gene-editing: Archive

Zacks Equity Research

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

RHHBYPositive Net Change SRPTPositive Net Change ARWRPositive Net Change